Breaking News Instant updates and real-time market news.

BCRX

BioCryst

$4.96

0.03 (0.61%)

, RCM

R1 RCM

$3.23

-0.03 (-0.92%)

04:55
09/07/17
09/07
04:55
09/07/17
04:55

Baird to hold a conference

Global Healthcare Conference 2017 is being held in New York on September 6-7.

BCRX

BioCryst

$4.96

0.03 (0.61%)

RCM

R1 RCM

$3.23

-0.03 (-0.92%)

JNCE

Jounce Therapeutics

$15.43

-0.29 (-1.84%)

LHCG

LHC Group

$65.62

-0.54 (-0.82%)

TECH

Bio-Techne

$121.66

0.51 (0.42%)

PXD

Pioneer Natural

$133.08

1.95 (1.49%)

ADRO

Aduro Biotech

$11.65

-0.05 (-0.43%)

CBM

Cambrex

$51.30

-0.2 (-0.39%)

CRL

Charles River

$107.86

0.41 (0.38%)

CAH

Cardinal Health

$68.61

1.09 (1.61%)

HCA

HCA Holdings

$77.28

-1.03 (-1.32%)

RARE

Ultragenyx

$52.78

-1.74 (-3.19%)

MYOV

Myovant Sciences

$12.25

-0.63 (-4.89%)

  • 07

    Sep

  • 07

    Sep

  • 08

    Sep

  • 10

    Sep

  • 11

    Sep

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Nov

  • 16

    Nov

BCRX BioCryst
$4.96

0.03 (0.61%)

09/06/17
JEFF
09/06/17
UPGRADE
Target $7
JEFF
Buy
BioCryst upgraded to Buy with $7 target at Jefferies
Jefferies analyst Maury Raycroft upgraded BioCryst Pharmaceuticals to Buy from Hold and raised his price target for the shares to $7 from $5. The final APeX-1 data readout gives BCX7353 a better chance of success in a Phase III trial, Raycroft tells investors in a research note. Further, the analyst sees increased potential for eventual approval given the need for an oral option. Raycroft views BioCryst shares as undervalued. JPMorgan last night also upgraded BioCryst.
09/06/17
JEFF
09/06/17
UPGRADE
JEFF
Buy
BioCryst upgraded to Buy from Hold at Jefferies
09/06/17
JPMS
09/06/17
UPGRADE
Target $9
JPMS
Overweight
BioCryst upgraded to Overweight with $9 target at JPMorgan
JPMorgan analyst Jessica Fye after the close last night upgraded BioCryst Pharmaceuticals to Overweight from Neutral and raised her price target for the shares to $9 from $6. The shares closed yesterday down 7c to $4.93. The analyst views the company's final results from the APeX-1 trial for BCX7353 in the prevention of hereditary angioedema attacks as encouraging. The results confirm an effective HAE attack prevention agent and one that justifies a valuation greater than the company's current $400M market capitalization, Fye tells investors in a research note.
09/05/17
JPMS
09/05/17
UPGRADE
JPMS
Overweight
BioCryst upgraded to Overweight from Neutral at JPMorgan
RCM R1 RCM
$3.23

-0.03 (-0.92%)

JNCE Jounce Therapeutics
$15.43

-0.29 (-1.84%)

02/21/17
02/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap Inc (SNAP) initiated with a Neutral rating and a $14 price target at Atlantic Equities, who said that expansion beyond the core audience is likely challenging, sustainability of engagement concerns will persist, and margins are structurally lower than peers. 2. REV Group (REVG) initiated with an Outperform at Credit Suisse. 3. Nokia (NOK) initiated with a Buy at Craig-Hallum. 4. Freeport McMoRan (FCX) initiated with a Neutral at Citi. 5. Jounce Therapeutics (JNCE) initiated with an Outperform at Cowen, with an Outperform at Wells Fargo and with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/17
COWN
02/21/17
INITIATION
COWN
Outperform
Jounce Therapeutics initiated with an Outperform at Cowen
Cowen analyst Boris Peaker started Jounce Therapeutics with an Outperform rating and no price target. The analyst believes JTX-2011 can have clinical utility in a wide range of malignancies and notes the company is well capitalized.
02/21/17
JPMS
02/21/17
INITIATION
Target $28
JPMS
Overweight
Jounce Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Cory Kasimov started Jounce Therapeutics with an Overweight rating and $28 price target. The analyst believes current share levels offer an attractive entry for the pure play immuno-oncology company.
02/21/17
WELS
02/21/17
INITIATION
WELS
Outperform
Jounce Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Jounce Therapeutics with an Outperform rating and $30-$33 price target range. The analyst cites the company's "industry-leading translational science effort on identifying novel immuno-oncology targets."
LHCG LHC Group
$65.62

-0.54 (-0.82%)

08/21/17
BOFA
08/21/17
INITIATION
Target $76
BOFA
Buy
LHC Group initiated with a Buy at BofA/Merrill
BofA/Merrill initiated LHC Group with a Buy and a $76 price target.
08/02/17
RHCO
08/02/17
NO CHANGE
RHCO
LHC Group joint ventures positive, says SunTrust
SunTrust analyst David S. MacDonald says that two new joint ventures recently announced by LHC are "meaningful" and can grow significantly. The analyst expects the company to report roughly in-line Q2 results this afternoon and keeps a $72 price target and a Buy rating on the stock.
07/26/17
JEFF
07/26/17
NO CHANGE
JEFF
Jefferies sees home nursing rate cuts less than 50 basis points in 2019
As investors feared, Centers for Medicare & Medicaid Services proposed to restructure its reimbursement system in 2019, which could translate to a home nursing rate cut of up to 6% in 2019, Jefferies analyst Brian Tanquilut says in a research note. He adds that CMS has noted openness to a longer phase-in of this cut. He believes the net rate cuts, assuming a two-year phase in of the Home Health Groupings Model, would amount to less than 50 basis points in 2019. It is also noteworthy that fee-for-service Medicare home nursing only represents 51% of Almost Family's (AFAM) sales, 55% of Amedisys', and 59% of LHC Group's (LHCG), the analyst writes. Tanquilut believes the three week delay in the home health proposal's release drove the stocks down and "somewhat" baked the news into valuations.
08/16/17
JEFF
08/16/17
NO CHANGE
JEFF
CMS proposal to have little impact on home nursing providers, says Jefferies
Centers for Medicare and Medicaid Services' proposal last night, seeking to scale down the joint replacement bundled program and eliminate the cardiac rehab bundle program, will have minimal impact on home nursing providers, if finalized as proposed, Jefferies analyst Brian Tanquilut tells investors in a research note. The analyst's checks suggest that provider referral patterns have already shifted and are unlikely to reverse, even absent Care for Joint Replacement's incentives. He notes that Almost Family (AFAM), Amedisys (AMED) and LHC Group (LHCG) have seen fairly minimal benefit to-date from the Comprehensive Care for Joint Replacement program.
TECH Bio-Techne
$121.66

0.51 (0.42%)

03/27/17
JANY
03/27/17
DOWNGRADE
JANY
Neutral
Bio-Techne downgraded to Neutral from Buy at Janney Capital
08/30/17
DBAB
08/30/17
NO CHANGE
Target $132
DBAB
Buy
Bio-Techne filing delay does not change thesis, says Deutsche Bank
Deutsche Bank analyst Dan Leonard says Bio-Techne's delayed annual filing is related to material weaknesses identified in internal controls related to Sarbanes Oxley and not to the financials themselves. The news does alter his thesis that the company's accelerating revenue growth profile could sustain its premium valuation. Bio-Techne is the "top strategic asset in an increasingly target-poor life science tools industry," Leonard tells investors in a research note. He keeps a Buy rating on the shares with a $132 price target.
07/13/17
WELS
07/13/17
INITIATION
Target $110
WELS
Market Perform
Bio-Techne initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans started Bio-Techne with a Market Perform rating and $110 price target. The analyst believes high expectations are priced into the stock.
02/09/17
02/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ulta Beauty (ULTA) initiated with a Hold at Loop Capital. 2. Spark Therapeutics (ONCE) initiated with an Outperform at Leerink. 3. GTT Communications (GTT) initiated with a Buy at BTIG. 4. Westlake Chemical (WLK) initiated with a Buy at Citi. 5. Bio-Techne (TECH) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PXD Pioneer Natural
$133.08

1.95 (1.49%)

08/09/17
GSCO
08/09/17
NO CHANGE
GSCO
Buy
Pioneer Natural share pullback overdone, says Goldman Sachs
Goldman analyst Brian Singer said the recent sharp pullback in Pioneer Natural shares is overdone. The analyst said lowered 2017 oil mix guidance is being incorrectly interpreted by the Street as a negative for Permian economics. Singer does not believe there has been any underperformance of oil production to more gas and the same oil and reiterates his Buy rating.
08/22/17
IMPC
08/22/17
INITIATION
Target $160
IMPC
Outperform
Pioneer Natural initiated with an Outperform at Imperial Capital
Imperial Capital analyst Irene Haas initiated Pioneer Natural with an Outperform and a $160 price target saying it is a first mover and leader in the Midland Basin. Recent drilling issues are being remediated and concerns of much gassier Midland Basin are overdone, the analyst wrote. Haas views Pioneer as a high growth, low net debt opportunity.
08/29/17
JEFF
08/29/17
NO CHANGE
Target $25
JEFF
Buy
Jefferies cuts oil forecast, Exploration & Production price targets
Jefferies lowered its Brent estimate to $57 per barrel from $64 in 2018, to $60 from $67 in 2019, and to $65 from $70 in 2020. The market appears to be adequately supplied in the near term, but depleting proved developed reserves and shrinking spare capacity should support rising longer-term price assumption, analyst Michael Hsu tells investors in a research note. To reflect the reduced forecast, the analyst cut his price targets for names in the Exploration & Production space. Target cuts include Buy-rated Carrizo Oil & Gas (CRZO) to $25 from $32, Buy-rated Continental Resources (CLR) to $42 from $52, Buy-rated Newfield Exploration (NFX) to $40 from $46, Buy-rated Noble Energy (NBL) to $32 from $36, Buy-rated Oasis Petroleum (OAS) to $13 from $16, Buy-rated Pioneer Natural Resources (PXD) to $171 from $192 and Buy-rated Range Resources (RRC) to $36 from $37.
08/22/17
08/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Redfin (RDFN) initiated with a Sector Perform at RBC Capital, Hold rating at Stifel, an Outperform at Oppenheimer and Neutral at Goldman Sachs. 2. Energen (EGN) initiated with an Outperform at Imperial Capital. 3. Pioneer Natural (PXD) initiated with an Outperform at Imperial Capital. 4. Revance (RVNC) initiated with an Outperform at JMP Securities. 5. Pacira (PCRX) initiated with a Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ADRO Aduro Biotech
$11.65

-0.05 (-0.43%)

05/01/17
RODM
05/01/17
INITIATION
Target $18
RODM
Buy
Aduro Biotech initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Aduro Biotech with an Outperform rating and $18 price target. The company is building a broad portfolio of immuno-oncology assets, the analyst contends.
07/18/17
COWN
07/18/17
INITIATION
COWN
Outperform
Aduro Biotech initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Aduro Biotech with an Outperform saying its three distinct immune-oncology platforms strongly position them as an emerging leader in oncology, and its $2.4B worth deals with pharma provides validation. He believes Auduro's proprietary platforms remain underappreciated by investors for their ability to target all the nodes of the cancer-immunity cycle. Shibutani said the future of immune-oncology is all about combo therapies and Aduro's extensive pipeline positions them to streamline clinical development of a wide range of interesting combinations.
03/07/17
03/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aduro Biotech (ADRO) reinitiated with a Buy at Roth Capital. 2 Foundation Building Materials (FBM) initiated with a Buy at SunTrust and Citi, an Outperform at Raymond James and RBC Capital, and an Overweight at Barclays. 3. Coca-Cola European Partners (CCE) initiated with a Buy at Argus. 4. Agrium (AGU) initiated with an Outperform at Bernstein. 5. Teleflex (TFX) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/17
ROTH
03/07/17
INITIATION
Target $17
ROTH
Buy
Aduro Biotech reinitiated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach reinitiated Aduro Biotech with a Buy rating and $17 price target based on a sum-of-parts, probability-adjusted NPV analysis. The analyst believes the company has assembled an "impressive collection of immuno-oncology assets" and has demonstrated encouraging proof-of-concept clinical results in mesothelioma.
CBM Cambrex
$51.30

-0.2 (-0.39%)

11/07/16
FANA
11/07/16
UPGRADE
Target $54
FANA
Overweight
Cambrex upgraded to Overweight from Equal-Weight at First Analysis
First Analysis analyst Steven Schwartz upgraded Cambrex to Overweight saying the company's Q3 results indicated that earnings growth should be strong in 2017 and 2018. The analyst has a $54 price target for the shares.
02/06/17
CHLM
02/06/17
NO CHANGE
Target $70
CHLM
Buy
Cambrex price target raised to $70 from $60 at Craig-Hallum
Craig-Hallum analyst Matt Tiampo raised his price target for Cambrex to $70 from $60 after the company reported "strong" Q4 results with "solid" growth on tap for 2017. The analyst believes Cambrex is "uniquely positioned" to take advantage of continued pharmaceutical volume growth and generate excess returns for shareholders. He reiterates a Buy rating on the shares.
02/06/17
SPHN
02/06/17
NO CHANGE
Target $61
SPHN
Overweight
Cambrex price target raised to $61 from $54 at Stephens
Stephens analyst Drew Jones raised his price target for Cambrex to $61 from $54 after the company capped off another "solid year" with Q4 results that exceeded expectations across the board. The analyst reiterates an Overweight rating on the shares.
09/27/16
SPHN
09/27/16
NO CHANGE
Target $56
SPHN
Overweight
Cambrex price target lowered to $56 from $63 at Stephens
Stephens analyst Drew Jones lowered his price target for Cambrex to $56 from $63 given the recent pullback in the stock. The analyst believes the recently announced acquisition of PharmaCore broadens the opportunity for Cambrex as it presents the chance to secure relationships much earlier in the regulatory process. Jones continues to like Cambrex's long-term outlook and reiterates an Overweight rating on its shares.
CRL Charles River
$107.86

0.41 (0.38%)

01/04/17
01/04/17
UPGRADE
Target $86.5

Buy
Charles River upgraded to Buy on robust demand, earnings growth at Evercore ISI
As previously reported, Evercore ISI upgraded Charles River to Buy from Hold and with an $86.50 price target. Analyst Ross Muken said his upgrade hinges on three key items, robust biopharma demand is likely to continue and benefit discovery/early development, fears of margin degradation from a mix shift are overblown, and management has a stellar capital allocation track record that has led to significant TSR. Muken adds Charles River's current discount provides a favorable entry point for investors looking for upside from double digit earnings growth.
02/14/17
BARD
02/14/17
NO CHANGE
Target $100
BARD
Outperform
Charles River price target raised to $100 from $89 at Baird
Baird analyst Eric Coldwell raised Charles River's price target to $100 following the Q4 beat and guidance. Coldwell reiterates his Outperform rating and said valuation isn't stretched and secular trends and catalysts are favorable.
02/15/17
BARD
02/15/17
NO CHANGE
Target $100
BARD
Outperform
Charles River price target raised to $100 from $89 at Baird
Baird analyst Eric Coldwell raised his price target on Charles River Labs to $100 from $89 as he said the company is firing on all cylinders. He believes the shares have room to run as the valuation is not stretched and secular trends and catalysts are ahead. Coldwell reiterated his Outperform rating on Charles River shares.
05/12/17
RHCO
05/12/17
NO CHANGE
RHCO
Charles River weakness unjustified, says SunTrust
SunTrust analyst Sandy Draper believes that Charles River reported "solid" results.He thinks investors are worried that the company's lower than expected Discovery and Safety Assessment revenue "indicates a cycle top for early-stage research." The analyst disagrees with this assessment ,partly because of the company's "rapidly accelerating bookings growth in March." He thinks the stock's weakness has created a good buying opportunity and keeps a $105 price target on the name.
CAH Cardinal Health
$68.61

1.09 (1.61%)

08/03/17
FBCO
08/03/17
NO CHANGE
Target $81
FBCO
Outperform
Cardinal Health price target lowered to $81 from $87 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for Cardinal Health to $81 from $87, citing on a "surprising" cut to 2018 EPS guidance primarily on incremental investment initiatives across its businesses, further defining 2018 as a transition year. The analyst reiterates an Outperform rating on the shares.
08/09/17
BARD
08/09/17
NO CHANGE
BARD
Neutral
AmerisourceBergen settlement ups odds of PharMerica switch, says Baird
Baird analyst Eric Coldwell said AmerisourceBergen's (ABC) 10-Q last week showed that the company and PharMerica (PMC) have tentatively agreed to settle their long-running legal fight, which he reads as significantly increasing the odds of AmerisourceBergen displacing incumbent Cardinal Health (CAH) after KKR (KKR) and minority investor Walgreens (WBA) complete their deal to buy PharMerica. Coldwell has a Neutral rating and $89 price target on AmerisourceBergen shares.
07/03/17
BARD
07/03/17
NO CHANGE
Target $75
BARD
Neutral
Cardinal Health confirms deal to buy Liberty Medical, says Baird
Baird analyst Eric Coldwell said that Cardinal Health has confirmed a deal to buy Liberty Medical, a direct-to-patient provider of diabetes supplies and products that is well known for its commercials featuring actor Wilford Brimley. The small deal, which is immaterial to his model, enhances Cardinal's direct-to-patient platform primarily in diabetes and likely also adds volume in ostomy and urology, Coldwell tells investors. He keeps a Neutral rating and $75 price target on Cardinal Health shares.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $87
FBCO
Outperform
Cardinal Health price target raised to $87 from $81 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Cardinal Health to $87 from $81 given the company's recent acquisition of Medtronic's patient recovery business. The analyst reiterates an Outperform rating on the shares.
HCA HCA Holdings
$77.28

-1.03 (-1.32%)

08/22/17
JPMS
08/22/17
NO CHANGE
JPMS
Neutral
Tenet 'short squeeze' shouldn't be chased, says JPMorgan
JPMorgan analyst Gary Taylor attributes Tenet's (THC) 32% advance over the last two sessions to a combination of several factors - a "short squeeze" due to fears of more activist activity; the timing of the announcement of Glenview Capital's resignation of two board seats and intention to "evaluate other avenues to be a constructive owner" during the thinly-traded final half of August; and competitors' Sum-of-the-Parts valuations that he deems "unreasonable." Taylor, who believes HCA Holdings (HCA) and other local systems will continue to have interest in certain Tenet hospitals, but is "somewhat skeptical that HCA would consider an outright purchase," would not be chasing the short squeeze and keeps a Neutral rating on Tenet shares.
08/28/17
JEFF
08/28/17
NO CHANGE
JEFF
Buy
HCA has 11% of its beds in Harvey impacted areas, says Jefferies
Jefferies analyst Brian Tanquilut points out that HCA Holdings (HCA) has 11% of its beds in areas impacted by severe weather from Hurricane Harvey. The analyst expects the hurricane to cause a "notable disruption," specifically for hospitals, physician offices, surgery centers, and labs. Investors are likely to take a long-term view of Hurricane Harvey, however, as it is a one-time issue and thus excluded from operating and financial results, Tanquilut tells investors in a research note. He sees both Tenet (THC) and Community Health (CYH) being minimally impacted from the storm. Envision Healthcare's (EVHC) AmSurg segment has three ambulatory surgery centers in the impacted markets, while Surgery Partners (SGRY) has only one facility in Houston, the analyst adds.
09/06/17
CANT
09/06/17
NO CHANGE
CANT
Overweight
Irma threat a risk for HCA, public hospital peers, says Cantor
Cantor Fitzgerald analyst Joseph France noted that HCA Holdings (HCA), Community Health (CYH), LifePoint (LPNT), Tenet (THC) and Envision Healthcare (EVHC) all have business in Florida and Texas and are all down today on the potential threat from Hurricane Irma and the impact from Hurricane Harvey last week. HCA reports nearly half of its beds are in Florida and Texas while Envision has said in the past that more than half of its anesthesia business and about half of its legacy ER business is in those two states, noted France, who adds that Community Health, LifePoint and Tenet are less exposed to those states. The analyst keeps an Overweight rating on HCA shares.
08/16/17
PIPR
08/16/17
NO CHANGE
PIPR
Piper 'incrementally more bearish' on Hospital sector
Valuations in the Hospital sector have come in, but not enough, Piper Jaffray analyst Sarah James tells investors in a research note. She believes that contradictory to what the hospitals are suggesting, structural headwinds will continue for five-plus years. The analyst believes the group should be trading at a discount. James has an Underweight rating on Community Health Systems (CYH), Overweight ratings on HCA Holdings (HCA) and Universal Health (UHS), and Neutral ratings on LifePoint (LPNT) and Tenet (THC).
RARE Ultragenyx
$52.78

-1.74 (-3.19%)

08/23/17
LEER
08/23/17
NO CHANGE
Target $83
LEER
Outperform
Ultragenyx price target lowered to $83 from $89 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Ultragenyx to $83 from $89 after the company announced disappointing Phase 3 GNE myopathy results that missed both primary and secondary endpoints when evaluating aceneuramic acid extended release. The analyst reiterates an Outperform rating on the shares.
08/23/17
RHCO
08/23/17
DOWNGRADE
Target $55
RHCO
Hold
Ultragenyx downgraded to Hold from Buy at SunTrust
SunTrust analyst Edward Nash downgraded Ultragenyx to Hold and slashed its price target to $55 from $105 after the company reported negative topline data from the Phase III trial for Ace-ER for GNE myopathy. Nash is disappointed by this first major clinical setback for the company and removed Ace-ER from his valuation models.
08/23/17
08/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ultragenyx (RARE) downgraded to Hold from Buy at SunTrust, with analyst Edward Nash slashing his price target to $55 from $105 after the company reported negative topline data from the Phase III trial for Ace-ER for GNE myopathy. Nash is disappointed by this first major clinical setback for the company and removed Ace-ER from his valuation models. 2. Duluth Holdings (DLTH) downgraded to Market Perform from Outperform at Raymond James, with analyst Dan Wewer citing increasing industry challenges. Wewer is concerned about increasing promotional activity and aggressive pricing tactics by competitors. 3. Cree (CREE) downgraded to Underweight from Equal Weight at Stephens. 4. Washington Prime (WPG) downgraded to Underperform from Neutral at Boenning & Scattergood by analyst Floris van Dijkum due to a more expensive NAV relative valuation caused by the more than 6% sector outperformance in the current quarter. 5. Baozun (BZUN) downgraded to Hold from Buy at Deutsche Bank by analyst Eileen Deng citing valuation after the stock's 18% rise in the past six months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/17
LEHM
09/06/17
INITIATION
Target $60
LEHM
Equal Weight
Ultragenyx initiated with an Equal Weight at Barclays
Barclays analyst Gena Wang started Ultragenyx with an Equal Weight rating and $60 price target.
MYOV Myovant Sciences
$12.25

-0.63 (-4.89%)

11/21/16
SBSH
11/21/16
INITIATION
Target $17
SBSH
Buy
Myovant Sciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Myovant Sciences (MYOV) with a Buy rating and $17 price target. The analyst sees upside if the company meets enrollment timelines through 2017. Myovant's Relagolix is validated by Neurocrine's (NBIX) Elagolix, but may have greater convenience and efficacy, Karnauskas contends.
11/21/16
COWN
11/21/16
INITIATION
Target $11
COWN
Outperform
Myovant Sciences initiated with an Outperform at Cowen
Cowen analyst Phil Nadeau initiated Myovant Sciences with an Outperform rating and $11 price target as he believes its Relugolix drug potential is undervalued. He noted it reported a strong proof of concept and should enter pivotal programs in 1H 2017, while projecting peak sales of more than $2B.
11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/17
EVER
08/16/17
INITIATION
Target $35
EVER
Outperform
Myovant Sciences initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Myovant Sciences with an Outperform and a $35 price target.

TODAY'S FREE FLY STORIES

JOE

Saint Joe Co.

$18.60

0.45 (2.48%)

16:46
09/22/17
09/22
16:46
09/22/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Saint Joe Co. »

Fairholme raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
09/22/17
09/22
16:40
09/22/17
16:40
General news
Moody's downgrades UK's rating to Aa2, changes outlook to stable »

Moody's Investors…

A

Agilent

$65.78

-0.14 (-0.21%)

, MRK

Merck

$65.13

-0.47 (-0.72%)

16:36
09/22/17
09/22
16:36
09/22/17
16:36
Hot Stocks
Agilent receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 »

Agilent Technologies…

A

Agilent

$65.78

-0.14 (-0.21%)

MRK

Merck

$65.13

-0.47 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

TYHT

Shineco

$3.23

-0.45 (-12.23%)

16:35
09/22/17
09/22
16:35
09/22/17
16:35
Hot Stocks
Shineco enters into strategic cooperation to establish Apocynum Industrial Park »

Shineco announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:34
09/22/17
09/22
16:34
09/22/17
16:34
Hot Stocks
Appliance Recycling gets written notice of default »

On September 20,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNVA

Rennova Health

$0.22

0.0086 (4.07%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Rennova Health announces 1 for 15 reverse stock split »

Rennova Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Breaking Hot Stocks news story on Appliance Recycling »

Appliance Recycling gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/22/17
09/22
16:30
09/22/17
16:30
Options
Preliminary option volume of 13.9M today »

Preliminary option volume…

EKSO

Ekso Bionics

$1.28

0.14 (12.28%)

16:23
09/22/17
09/22
16:23
09/22/17
16:23
Hot Stocks
Ekso Bionics awarded government contract »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

, AET

Aetna

$153.57

0.18 (0.12%)

16:22
09/22/17
09/22
16:22
09/22/17
16:22
General news
On The Fly: Top stock stories for Friday »

The major averages…

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CI

Cigna

$182.74

0.61 (0.33%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

FSLR

First Solar

$51.41

2.65 (5.43%)

FINL

Finish Line

$9.73

0.51 (5.53%)

ASND

Ascendis Pharma

$34.24

6.5 (23.43%)

VSAR

Versartis

$2.68

-18.925 (-87.62%)

ICPT

Intercept

$61.59

-12.11 (-16.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DLR

Digital Realty

$114.51

-1.72 (-1.48%)

16:19
09/22/17
09/22
16:19
09/22/17
16:19
Syndicate
Breaking Syndicate news story on Digital Realty »

Digital Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:17
09/22/17
09/22
16:17
09/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$69.09

0.28 (0.41%)

16:16
09/22/17
09/22
16:16
09/22/17
16:16
Hot Stocks
TSYS announces resignation of COO Pamela Joseph »

TSYS announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
09/22/17
09/22
16:16
09/22/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$170.54

-0.57 (-0.33%)

16:15
09/22/17
09/22
16:15
09/22/17
16:15
Hot Stocks
Facebook's Zuckerberg plans to sell up to 75M shares to fund charity initiatives »

On September 22 Mr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

IDA

IDACORP

$87.79

-0.73 (-0.82%)

16:13
09/22/17
09/22
16:13
09/22/17
16:13
Hot Stocks
IDACORP raises quarterly dividend 7.3% to 59c per share »

The dividend declaration,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRX

Valeritas

$3.06

-0.23 (-6.99%)

16:13
09/22/17
09/22
16:13
09/22/17
16:13
Syndicate
Valeritas announces common stock purchase agreement by Aspire Capital »

Valeritas Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$170.54

-0.57 (-0.33%)

16:12
09/22/17
09/22
16:12
09/22/17
16:12
Hot Stocks
Facebook dumps plan for new class of shares »

On September 21 the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

DCIX

Diana Containerships

$0.42

-0.0373 (-8.16%)

16:11
09/22/17
09/22
16:11
09/22/17
16:11
Hot Stocks
Diana Containerships announces one-for-three reverse stock split »

Diana Containerships…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEP

Spectra Energy Partners

$43.89

0.34 (0.78%)

16:10
09/22/17
09/22
16:10
09/22/17
16:10
Syndicate
Breaking Syndicate news story on Spectra Energy Partners »

Spectra Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEV

Sevcon

$22.04

0.04 (0.18%)

, BWA

BorgWarner

$50.00

0.41 (0.83%)

16:10
09/22/17
09/22
16:10
09/22/17
16:10
Hot Stocks
Sevcon stockholders approve acquisition by BorgWarner »

Sevcon (SEV) announced…

SEV

Sevcon

$22.04

0.04 (0.18%)

BWA

BorgWarner

$50.00

0.41 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Oct

ATOS

Atossa Genetics

$0.49

-0.0296 (-5.71%)

16:07
09/22/17
09/22
16:07
09/22/17
16:07
Syndicate
Breaking Syndicate news story on Atossa Genetics  »

Atossa Genetics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$142.68

-0.27 (-0.19%)

16:06
09/22/17
09/22
16:06
09/22/17
16:06
Hot Stocks
Chubb CEO issues statement on EU-U.S. covered agreement »

Evan Greenberg, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 31

    Jan

AAPL

Apple

$153.39

-2.68 (-1.72%)

15:40
09/22/17
09/22
15:40
09/22/17
15:40
Options
Active trading in Apple as iPhone 8 makes a debut »

Active trading in Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

MRK

Merck

15:39
09/22/17
09/22
15:39
09/22/17
15:39
Hot Stocks
Merck gets FDA approval for Keytruda »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.